These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

490 related articles for article (PubMed ID: 25810490)

  • 1. IL8-CXCR2 pathway inhibition as a therapeutic strategy against MDS and AML stem cells.
    Schinke C; Giricz O; Li W; Shastri A; Gordon S; Barreyro L; Bhagat T; Bhattacharyya S; Ramachandra N; Bartenstein M; Pellagatti A; Boultwood J; Wickrema A; Yu Y; Will B; Wei S; Steidl U; Verma A
    Blood; 2015 May; 125(20):3144-52. PubMed ID: 25810490
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antisense STAT3 inhibitor decreases viability of myelodysplastic and leukemic stem cells.
    Shastri A; Choudhary G; Teixeira M; Gordon-Mitchell S; Ramachandra N; Bernard L; Bhattacharyya S; Lopez R; Pradhan K; Giricz O; Ravipati G; Wong LF; Cole S; Bhagat TD; Feld J; Dhar Y; Bartenstein M; Thiruthuvanathan VJ; Wickrema A; Ye BH; Frank DA; Pellagatti A; Boultwood J; Zhou T; Kim Y; MacLeod AR; Epling-Burnette PK; Ye M; McCoon P; Woessner R; Steidl U; Will B; Verma A
    J Clin Invest; 2018 Dec; 128(12):5479-5488. PubMed ID: 30252677
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Identification of campath-1 (CD52) as novel drug target in neoplastic stem cells in 5q-patients with MDS and AML.
    Blatt K; Herrmann H; Hoermann G; Willmann M; Cerny-Reiterer S; Sadovnik I; Herndlhofer S; Streubel B; Rabitsch W; Sperr WR; Mayerhofer M; Rülicke T; Valent P
    Clin Cancer Res; 2014 Jul; 20(13):3589-602. PubMed ID: 24799522
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Overexpression of IL-1 receptor accessory protein in stem and progenitor cells and outcome correlation in AML and MDS.
    Barreyro L; Will B; Bartholdy B; Zhou L; Todorova TI; Stanley RF; Ben-Neriah S; Montagna C; Parekh S; Pellagatti A; Boultwood J; Paietta E; Ketterling RP; Cripe L; Fernandez HF; Greenberg PL; Tallman MS; Steidl C; Mitsiades CS; Verma A; Steidl U
    Blood; 2012 Aug; 120(6):1290-8. PubMed ID: 22723552
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Focal Adhesion Kinase as a Potential Target in AML and MDS.
    Carter BZ; Mak PY; Wang X; Yang H; Garcia-Manero G; Mak DH; Mu H; Ruvolo VR; Qiu Y; Coombes K; Zhang N; Ragon B; Weaver DT; Pachter JA; Kornblau S; Andreeff M
    Mol Cancer Ther; 2017 Jun; 16(6):1133-1144. PubMed ID: 28270436
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Expression of CDKN1C in the bone marrow of patients with myelodysplastic syndrome and secondary acute myeloid leukemia is associated with poor survival after conventional chemotherapy.
    Radujkovic A; Dietrich S; Andrulis M; Benner A; Longerich T; Pellagatti A; Nanda K; Giese T; Germing U; Baldus S; Boultwood J; Ho AD; Dreger P; Luft T
    Int J Cancer; 2016 Sep; 139(6):1402-13. PubMed ID: 27170453
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Role of IL8 in myeloid malignancies.
    Ramachandra N; Gupta M; Schwartz L; Todorova T; Shastri A; Will B; Steidl U; Verma A
    Leuk Lymphoma; 2023; 64(11):1742-1751. PubMed ID: 37467070
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Molecular pathways mediating MDS/AML with focus on AML1/RUNX1 point mutations.
    Harada Y; Harada H
    J Cell Physiol; 2009 Jul; 220(1):16-20. PubMed ID: 19334039
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Disruption of Wnt/β-Catenin Exerts Antileukemia Activity and Synergizes with FLT3 Inhibition in
    Jiang X; Mak PY; Mu H; Tao W; Mak DH; Kornblau S; Zhang Q; Ruvolo P; Burks JK; Zhang W; McQueen T; Pan R; Zhou H; Konopleva M; Cortes J; Liu Q; Andreeff M; Carter BZ
    Clin Cancer Res; 2018 May; 24(10):2417-2429. PubMed ID: 29463558
    [No Abstract]   [Full Text] [Related]  

  • 10. The Stat3/5 Signaling Biosignature in Hematopoietic Stem/Progenitor Cells Predicts Response and Outcome in Myelodysplastic Syndrome Patients Treated with Azacitidine.
    Miltiades P; Lamprianidou E; Vassilakopoulos TP; Papageorgiou SG; Galanopoulos AG; Kontos CK; Adamopoulos PG; Nakou E; Vakalopoulou S; Garypidou V; Papaioannou M; Hatjiharissi E; Papadaki HA; Spanoudakis E; Pappa V; Scorilas A; Tsatalas C; Kotsianidis I;
    Clin Cancer Res; 2016 Apr; 22(8):1958-68. PubMed ID: 26700206
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Targets of opportunity for precision medicine.
    Saunthararajah Y
    Blood; 2015 May; 125(20):3041-2. PubMed ID: 25977578
    [TBL] [Abstract][Full Text] [Related]  

  • 12. MicroRNA-9 promotes proliferation of leukemia cells in adult CD34-positive acute myeloid leukemia with normal karyotype by downregulation of Hes1.
    Tian C; You MJ; Yu Y; Zhu L; Zheng G; Zhang Y
    Tumour Biol; 2016 Jun; 37(6):7461-71. PubMed ID: 26678889
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Characterization of myelodysplastic syndromes hematopoietic stem and progenitor cells using mass cytometry.
    Bachas C; Duetz C; van Spronsen MF; Verhoeff J; Garcia Vallejo JJ; Jansen JH; Cloos J; Westers TM; van de Loosdrecht AA
    Cytometry B Clin Cytom; 2023 Mar; 104(2):128-140. PubMed ID: 35289472
    [TBL] [Abstract][Full Text] [Related]  

  • 14. CXCL12+ stromal cells as bone marrow niche for CD34+ hematopoietic cells and their association with disease progression in myelodysplastic syndromes.
    Abe-Suzuki S; Kurata M; Abe S; Onishi I; Kirimura S; Nashimoto M; Murayama T; Hidaka M; Kitagawa M
    Lab Invest; 2014 Nov; 94(11):1212-23. PubMed ID: 25199050
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Withaferin A suppresses the growth of myelodysplasia and leukemia cell lines by inhibiting cell cycle progression.
    Okamoto S; Tsujioka T; Suemori S; Kida J; Kondo T; Tohyama Y; Tohyama K
    Cancer Sci; 2016 Sep; 107(9):1302-14. PubMed ID: 27311589
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Overexpression of miR-125a in myelodysplastic syndrome CD34+ cells modulates NF-κB activation and enhances erythroid differentiation arrest.
    Gañán-Gómez I; Wei Y; Yang H; Pierce S; Bueso-Ramos C; Calin G; Boyano-Adánez Mdel C; García-Manero G
    PLoS One; 2014; 9(4):e93404. PubMed ID: 24690917
    [TBL] [Abstract][Full Text] [Related]  

  • 17. U2AF1 mutation promotes tumorigenicity through facilitating autophagy flux mediated by FOXO3a activation in myelodysplastic syndromes.
    Zhu Y; Song D; Guo J; Jin J; Tao Y; Zhang Z; Xu F; He Q; Li X; Chang C; Wu L
    Cell Death Dis; 2021 Jun; 12(7):655. PubMed ID: 34183647
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Up-regulation of SPINT2/HAI-2 by Azacytidine in bone marrow mesenchymal stromal cells affects leukemic stem cell survival and adhesion.
    Roversi FM; Cury NM; Lopes MR; Ferro KP; Machado-Neto JA; Alvarez MC; Dos Santos GP; Giardini Rosa R; Longhini AL; Duarte ADSS; Pericole FV; Favaro P; Yunes JA; Saad STO
    J Cell Mol Med; 2019 Feb; 23(2):1562-1571. PubMed ID: 30484958
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A synthetic cell-penetrating peptide derived from nuclear localization signal of EPS8 exerts anticancer activity against acute myeloid leukemia.
    Chen Y; Xie X; Wu A; Wang L; Hu Y; Zhang H; Li Y
    J Exp Clin Cancer Res; 2018 Jan; 37(1):12. PubMed ID: 29357910
    [TBL] [Abstract][Full Text] [Related]  

  • 20. SPARC silencing inhibits the growth of acute myeloid leukemia transformed from myelodysplastic syndrome via induction of cell cycle arrest and apoptosis.
    Nian Q; Xiao Q; Wang L; Luo J; Chen LP; Yang ZS; Liu L
    Int J Mol Med; 2014 Apr; 33(4):856-62. PubMed ID: 24535175
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 25.